Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.35
MDVN's Cash to Debt is ranked higher than
57% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. MDVN: 1.35 )
MDVN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.35

Equity to Asset 0.40
MDVN's Equity to Asset is ranked higher than
58% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MDVN: 0.40 )
MDVN' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.99
Current: 0.4

-0.02
0.99
F-Score: 6
Z-Score: 16.48
M-Score: -0.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 27.50
MDVN's Operating margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. MDVN: 27.50 )
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27   Max: 66.67
Current: 27.5

-510.27
66.67
Net-margin (%) 21.60
MDVN's Net-margin (%) is ranked higher than
93% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. MDVN: 21.60 )
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58   Max: 37.65
Current: 21.6

-496.58
37.65
ROE (%) 94.00
MDVN's ROE (%) is ranked higher than
99% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. MDVN: 94.00 )
MDVN' s 10-Year ROE (%) Range
Min: -862.65   Max: 2.1
Current: 94

-862.65
2.1
ROA (%) 25.52
MDVN's ROA (%) is ranked higher than
98% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. MDVN: 25.52 )
MDVN' s 10-Year ROA (%) Range
Min: -80.48   Max: 1.72
Current: 25.52

-80.48
1.72
ROC (Joel Greenblatt) (%) 216.73
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. MDVN: 216.73 )
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -201825   Max: -74.39
Current: 216.73

-201825
-74.39
Revenue Growth (%) 58.60
MDVN's Revenue Growth (%) is ranked higher than
97% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. MDVN: 58.60 )
MDVN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 60
Current: 58.6

0
60
EBITDA Growth (%) -19.00
MDVN's EBITDA Growth (%) is ranked higher than
65% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. MDVN: -19.00 )
MDVN' s 10-Year EBITDA Growth (%) Range
Min: -22.5   Max: 154.6
Current: -19

-22.5
154.6
EPS Growth (%) 4.50
MDVN's EPS Growth (%) is ranked higher than
82% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MDVN: 4.50 )
MDVN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 71
Current: 4.5

0
71
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MDVN Guru Trades in Q4 2013

Jim Simons 94,000 sh (New)
Steven Cohen 6,888 sh (+262.53%)
» More
Q1 2014

MDVN Guru Trades in Q1 2014

John Burbank 3,173 sh (New)
Mario Gabelli 15,046 sh (New)
Steven Cohen 216,962 sh (+3049.85%)
Jim Simons Sold Out
» More
Q2 2014

MDVN Guru Trades in Q2 2014

Mario Gabelli 25,046 sh (+66.46%)
John Burbank Sold Out
» More
Q3 2014

MDVN Guru Trades in Q3 2014

Joel Greenblatt 13,970 sh (New)
John Burbank 2,451 sh (New)
Paul Tudor Jones 11,585 sh (New)
Jim Simons 108,728 sh (New)
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy0.01%$69.58 - $102.26 $ 114.8335%13970
Mario Gabelli 2014-09-30 Sold Out 0.01%$69.58 - $102.26 $ 114.8335%0
John Burbank 2014-09-30 New Buy$69.58 - $102.26 $ 114.8335%2451
John Burbank 2014-06-30 Sold Out 0.01%$55.08 - $77.773 $ 114.8371%0
Mario Gabelli 2014-06-30 Add 66.46%$55.08 - $77.773 $ 114.8371%25046
John Burbank 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 114.8356%3173
Mario Gabelli 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 114.8356%15046
Andreas Halvorsen 2013-09-30 Sold Out 0.46%$53.22 - $60.66 $ 114.83101%0
Andreas Halvorsen 2013-06-30 Add 86.31%0.21%$45.21 - $55.06 $ 114.83128%1685216
Andreas Halvorsen 2013-03-31 Reduce -73.04%0.88%$42.63 - $57.71 $ 114.83124%904500
Andreas Halvorsen 2012-09-30 New Buy1.5%$44.85 - $56.9 $ 114.83131%3855254
George Soros 2012-03-31 Sold Out 0.1%$45.84 - $75.56 $ 114.8390%0
George Soros 2011-12-31 New Buy0.1%$15.79 - $48.8 $ 114.83244%50000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation Inc

Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and HomeAway Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc, and HomeAway Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 81.00
MDVN's P/E(ttm) is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 81.00 )
MDVN' s 10-Year P/E(ttm) Range
Min: 64.23   Max: 329.46
Current: 81

64.23
329.46
P/B 35.77
MDVN's P/B is ranked higher than
58% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. MDVN: 35.77 )
MDVN' s 10-Year P/B Range
Min: 0.18   Max: 1848.25
Current: 35.77

0.18
1848.25
P/S 17.13
MDVN's P/S is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. MDVN: 17.13 )
MDVN' s 10-Year P/S Range
Min: 4.54   Max: 563.33
Current: 17.13

4.54
563.33
PFCF 182.27
MDVN's PFCF is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 182.27 )
MDVN' s 10-Year PFCF Range
Min: 3.04   Max: 253.5
Current: 182.27

3.04
253.5
EV-to-EBIT 60.31
MDVN's EV-to-EBIT is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 60.31 )
MDVN' s 10-Year EV-to-EBIT Range
Min: -658.8   Max: 156.7
Current: 60.31

-658.8
156.7
Current Ratio 4.83
MDVN's Current Ratio is ranked higher than
73% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MDVN: 4.83 )
MDVN' s 10-Year Current Ratio Range
Min: 1.46   Max: 27.3
Current: 4.83

1.46
27.3
Quick Ratio 4.83
MDVN's Quick Ratio is ranked higher than
74% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. MDVN: 4.83 )
MDVN' s 10-Year Quick Ratio Range
Min: 1.46   Max: 27.3
Current: 4.83

1.46
27.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 82.61
MDVN's Price/Net Current Asset Value is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. MDVN: 82.61 )
MDVN' s 10-Year Price/Net Current Asset Value Range
Min: 0.38   Max: 1558.67
Current: 82.61

0.38
1558.67
Price/Tangible Book 35.77
MDVN's Price/Tangible Book is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. MDVN: 35.77 )
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 1152.75
Current: 35.77

0.3
1152.75
Price/DCF (Projected) 102.53
MDVN's Price/DCF (Projected) is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 102.53 )
MDVN' s 10-Year Price/DCF (Projected) Range
Min: 1.96   Max: 1002.5
Current: 102.53

1.96
1002.5
Price/Median PS Value 0.61
MDVN's Price/Median PS Value is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. MDVN: 0.61 )
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.46
Current: 0.61

0.16
2.46
Price/Graham Number 11.10
MDVN's Price/Graham Number is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 11.10 )
MDVN' s 10-Year Price/Graham Number Range
Min: 9.69   Max: 21.54
Current: 11.1

9.69
21.54
Earnings Yield (Greenblatt) 1.70
MDVN's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. MDVN: 1.70 )
MDVN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 2
Current: 1.7

0.6
2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany
Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI "enzalutamide" capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensit Oct 30 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 
Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, TER Feb 14 2012 
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 16,800 Shares Feb 11 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 4,200 Shares Feb 08 2011 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 10,000 Shares Jan 20 2010 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 20,000 Shares Dec 08 2009 

More From Other Websites
Joseph Lobacki to Become Medivation's Chief Commercial Officer Nov 25 2014
Joseph Lobacki to Become Medivation's Chief Commercial Officer Nov 25 2014
4:10 pm Medivation announced that Joseph Lobacki will join the co as CCO on Dec 8, 2014 Nov 25 2014
Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Nov 17 2014
Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Nov 17 2014
Street Talk: HOG, LULU, BMRN, MDVN & TRS Nov 14 2014
MEDIVATION, INC. Financials Nov 14 2014
10-Q for Medivation, Inc. Nov 08 2014
Another lackluster session for major equities Nov 07 2014
Clarification: Earns-Medivation story Nov 07 2014
Clarification: Earns-Medivation story Nov 07 2014
Medivation Hits High After Q3 Earnings Beat Nov 07 2014
Medivation Q3 Earnings, Revenues Lag Estimates Nov 07 2014
Medivation Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
Medivation Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
Q3 2014 Medivation Inc Earnings Release - After Market Close Nov 06 2014
Medivation Announces Participation at Upcoming Investor Conference Nov 05 2014
Medivation Announces Participation at Upcoming Investor Conference Nov 05 2014
Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK